Showing 161 - 180 results of 1,303 for search 'Eligible (novel)', query time: 0.17s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166

    In silico designing of a novel epitope-based candidate vaccine against Streptococcus pneumoniae with introduction of a new domain of PepO as adjuvant by Zohreh Bahadori, Mona Shafaghi, Hamid Madanchi, Mohammad Mehdi Ranjbar, Ali Akbar Shabani, Seyed Fazlollah Mousavi

    Published 2022-09-01
    “…Conclusions For the first time this work presents a novel vaccine consisting of epitopes of PspC, PhtD, and PsaA antigens which is adjuvanted with a new truncated domain of PepO. …”
    Get full text
    Article
  7. 167

    COVID-19 Clusters at Workplaces and its Transmission into Communities in Vietnam: A Novel Emerging Occupational Risk Factor at Work Due to Coronavirus Infection by Nhi Ngoc Yen Huynh, Dai Duc Nguyen, Nguyen Ha Ta, Minh Thien Nguyen, Tai Van Nguyen, Huy Thanh Dang, Tuyen Kim Cat Vo, Ngoan Tran Le

    Published 2020-08-01
    “…Conclusions: Because COVID-19 infection at workplaces was responsible for nearly one-third of the total patients, there was a novel emerged occupational risk factor at work due to coronavirus infection. …”
    Get full text
    Article
  8. 168
  9. 169

    A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study by Chen Sarbagili-Shabat, Lindsey Albenberg, Johan Van Limbergen, Naomi Pressman, Anthony Otley, Michal Yaakov, Eytan Wine, Dror Weiner, Arie Levine

    Published 2021-10-01
    “…The goal of the pilot trial was to evaluate the potential efficacy and feasibility of a novel UC exclusion diet (UCED) for clinical remission, as well as the potential of sequential antibiotics for diet-refractory patients to achieve remission without steroids. …”
    Get full text
    Article
  10. 170

    Effect of Food on the Pharmacokinetics and Safety of a Novel c-Met Inhibitor SCC244: A Randomized Phase I Study in Healthy Subjects by Wu J, Xu H, Li H, Ma L, Chen J, Yuan F, Sheng L, Liu C, Chen W, Li X

    Published 2023-03-01
    “…Tolerability was assessed by physical examination, vital sign measurements, 12-lead ECG, clinical laboratory tests, and adverse events (AEs) monitoring throughout the study.Results: Eighteen eligible subjects were enrolled in the study. The ratios (90% CI) of Cmax values for SCC244 in high-fat and low-fat meal states to that observed in fasted state were 194.8% (174.3– 217.7%) and 194.6% (174.1– 217.5%), respectively. …”
    Get full text
    Article
  11. 171
  12. 172
  13. 173
  14. 174

    Accelerating towards P. vivax elimination with a novel serological test-and-treat strategy: a modelling case study in BrazilResearch in context by Narimane Nekkab, Thomas Obadia, Wuelton M. Monteiro, Marcus V.G. Lacerda, Michael White, Ivo Mueller

    Published 2023-06-01
    “…Treatment with radical cure drugs fails to target the hidden asymptomatic and hypnozoite reservoirs in populations. PvSeroTAT, a novel serological test-and-treat intervention using a serological diagnostic to screen hypnozoite carriers for radical cure eligibility and treatment, could accelerate P. vivax elimination. …”
    Get full text
    Article
  15. 175
  16. 176

    Pharmacist-Physician Split-Shared Visits in a Federally Qualified Health Center: Lessons Learned from a Novel Reimbursement Model using Telehealth by Nada M. Abou-Karam, Melisssa E. Jump, Jingying Jiao, Andrew N. Schmelz

    Published 2022-03-01
    “…This article describes the experience and outcomes of the implementation of a novel, pharmacist-physician split-shared telehealth model at AltaMed Medical Group, a large, multi-site FQHC in Los Angeles and Orange counties.  …”
    Get full text
    Article
  17. 177
  18. 178
  19. 179
  20. 180

    Comparison of a novel tablet formulation of tacrolimus and conventional capsule formulation in de novo kidney transplant recipients: a systematic review and meta-analysis by Zhenyu Liu, Kexin Yin, Huiqian Liu, Ning Wang, Junjie Yao, Jiangtao Zhou, Yongxi Tang, Zhikang Yin

    Published 2023-12-01
    “…This study was registered with PROSPERO (registration number: CRD42023403787).Results: A total of seven eligible articles including 1,428 patients with 712 in the LCPT group versus 716 in the PR-Tac/IR-Tac group were included in this study for evidence synthesis. …”
    Get full text
    Article